Cofactor Genomics

Cofactor Genomics, a Predictive Immune Modeling company, today presented initial results from the PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) multicenter clinical trial at this week’s Advances in Genome Biology and Technology Precision Health Meeting. Data show that Cofactor's OncoPrism test using Predictive Immune Modeling was nearly twice as accurate as PD-L1 assays in determining patients that will benefit from immunotherapies such as Keytruda (pembrolizumab).

The PREDAPT clinical trial is studying whether a more comprehensive and quantitative profiling of the tumor micro-environment using the OncoPrism assay will lead to more accurate prediction of responders to immune checkpoint inhibitors across a variety of cancers, and thus provide better tools for informing and prioritizing treatment paths. The PREDAPT study currently includes 20 healthcare systems from across the nation and will ultimately study a total of 11 solid tumor cancers, including head and neck squamous cell carcinoma, non-small cell lung cancer, and melanoma.

In clinical studies where OncoPrism was tuned to have the same sensitivity as PD-L1, Cofactor’s test reached 75% accuracy in predicting responders to immune checkpoint inhibitors, when compared to 42% accuracy for PD-L1. These interim results from nine healthcare systems show at similar sensitivity, OncoPrism has greater specificity and continues to be superior to single analyte approaches like PD-L1. The staggering improvement in prediction is based on OncoPrism’s Predictive Immune Modeling platform of multidimensional RNA models that capture health-related state, compounded with machine learning to better understand disease and predict therapy response.

“This readout from a subset of our partnered healthcare systems across the U.S. suggests our multidimensional biomarker approach and resulting diagnostic will be broadly applicable across the patient population,” said Jarret Glasscock, CEO of Cofactor Genomics, “The study results provide a strong framework and understanding for the other important cancers we will be studying in our broader PREDAPT work, including non-small cell lung cancer (NSCLC).”

About PREDAPT

Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies (PREDAPT) is a national clinical trial sponsored by Cofactor Genomics working and in collaboration with the leaders in decentralized clinical trials, CureBase. The trial’s goal is to evaluate the predictive power of Cofactor’s Predictive Immune Modeling approach and the biomarkers generated to predict which patients will ultimately benefit from immune checkpoint inhibitors across 11 cancers.

About Cofactor Genomics

Cofactor Genomics is bridging the precision medicine gap by building diagnostic tools to match the right patient to the right treatment at the right time. Predicting patient response to therapy currently relies on isolated, single-analyte biomarkers that have failed to deliver accurate therapy response predictions, resulting in unnecessary healthcare costs, and most harmfully, negative outcomes for patients. Cofactor’s products use Predictive Immune Modeling, which leverages RNA data and machine learning to combine biological signals, creating multidimensional biomarkers to deliver on the promise of precision medicine. Cofactor Genomics offers its full-service molecular, informatic, and database tools to make drug discovery, clinical trials and therapy selection more successful.

Cofactor Genomics Unveils New Data Showing Novel OncoPrism Diagnostic is Nearly Twice as Accurate as PD-L1 in Identifying Immunotherapy Responders